The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
Open accessAbstract
OBJECTIVE: To appraise the evidence for comparative efficacy and tolerability of drug treatments in patients with generalised anxiety disorder. DESIGN: Systematic review of randomised controlled trials. Primary Bayesian probabilistic mixed treatment meta-analyses allowed pharmacological treatments to be ranked for effectiveness for each outcome measure, given as percentage probability of being the most effective treatment. Secondary frequentist mixed treatment meta-analyses conducted with random effects model; effect size reported as odds ratio and 95% confidence interval. DATA SOURCES: Medline, Embase, BIOSIS, PsycINFO, Health Economic Evaluations Database, National Health Service Economic Evaluation Database, and Database of Abstracts of Reviews of Effects via DataStar, and Cochrane Database of Systematic Reviews via Cochrane Library (January 1980 to February 2009). Eligibility criteria Double blind placebo controlled randomised controlled trials; published systematic reviews and meta-analyses of randomised controlled trials. Randomised controlled trials including adult participants (aged ≥ 18) receiving any pharmacological treatment for generalised anxiety disorder. Data abstraction methods Titles or abstracts reviewed initially, followed by review of full text publications for citations remaining after first pass. A three person team conducted screening; an independent reviewer checked a random selection (10%) of articles screened. Data extracted for meta-analysis were also independently reviewed. MAIN OUTCOME MEASURES: Proportion of participants experiencing ≥ 50% reduction from baseline score on Hamilton anxiety scale (HAM-A) (response), proportion with final HAM-A score ≤ 7 (remission), proportion withdrawing from trial because of adverse events (tolerability). RESULTS: The review identified 3249 citations, and 46 randomised controlled trials met inclusion criteria; 27 trials contained sufficient or appropriate data for inclusion in the analysis. Analyses compared nine drugs (duloxetine, escitalopram, fluoxetine, lorazepam, paroxetine, pregabalin, sertraline, tiagabine, and venlafaxine). In the primary probabilistic mixed treatment meta-analyses, fluoxetine was ranked first for response and remission (probability of 62.9% and 60.6%, respectively) and sertraline was ranked first for tolerability (49.3%). In a subanalysis ranking treatments for generalised anxiety disorder currently licensed in the United Kingdom, duloxetine was ranked first for response (third across all treatments; 2.7%), escitalopram was ranked first for remission (second across all treatments; 26.7%), and pregabalin was ranked first for tolerability (second across all treatments; 7.7%). CONCLUSIONS: Though the frequentist analysis was inconclusive because of a high level of uncertainty in effect sizes (based on the relatively small number of comparative trials), the probabilistic analysis, which did not rely on significant outcomes, showed that fluoxetine (in terms of response and remission) and sertraline (in terms of tolerability) seem to have some advantages over other treatments. Among five UK licensed treatments, duloxetine, escitalopram, and pregabalin might offer some advantages over venlafaxine and paroxetine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility
Lunn, D. J., Thomas, A., Best, N., & Spiegelhalter, D. (2000) · Statistics and Computing · doi:10.1023/a:1008929526011 · Cited by 5,368
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
(1920) · British Journal of Ophthalmology · doi:10.1136/bjo.4.1.25 · Cited by 1,606
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600 · cited 1×
“For the analyses in WinBUGS, every sample consisted of 20 000 iterations with an initial burn-in period of 1000 iterations. The model framework, stratified by study, included univariate random effects to allow for apparent heterogeneity between studies in the treatment comparison effects. The probability of the outcom…”
MethodEvaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Bayesian methods in meta-analysis and evidence synthesis
Sutton, A. J., & Abrams, K. R. (2001) · Statistical Methods in Medical Research · doi:10.1177/096228020101000404 · Cited by 710
(2002) · PubMed · Cited by 518
Human and economic burden of generalized anxiety disorder
Hoffman, D. L., Dukes, E. M., & Wittchen, H.-U. (2008) · Depression and Anxiety · doi:10.1002/da.20257 · Cited by 438
Pregabalin in Generalized Anxiety Disorder: A Placebo-Controlled Trial
Pande, A. C., Crockatt, J. G., Feltner, D. E., Janney, C. A., Smith, W. T., Weisler, R., Londborg, P. D., Bielski, R. J., Zimbroff, D. L., Davidson, J. R. T., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.3.533 · Cited by 314
Davidson, J. R. T., DuPont, R. L., Hedges, D., & Haskins, J. T. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0805 · Cited by 303
Hartford, J., Kornstein, S., Liebowitz, M., Pigott, T., Russell, J., Detke, M., Walker, D., Ball, S., Dunayevich, E., Dinkel, J., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32807fb1b2 · Cited by 286
Rickels, K., Pollack, M. H., Feltner, D. E., Lydiard, R. B., Zimbroff, D. L., Bielski, R. J., Tobias, K., Brock, J. D., Zornberg, G. L., & Pande, A. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.1022 · Cited by 280
Feltner, D. E., Crockatt, J. G., Dubovsky, S. J., Cohn, C. K., Shrivastava, R. K., Targum, S. D., Liu-Dumaw, M., Carter, C. M., & Pande, A. C. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084032.22282.ff · Cited by 260
Pollack, M. H., Zaninelli, R., Goddard, A., McCafferty, J. P., Bellew, K. M., Burnham, D. B., & Iyengar, M. K. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0508 · Cited by 246
Montgomery, S. A., Tobias, K., Zornberg, G. L., Kasper, S., & Pande, A. C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0511 · Cited by 211
Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study
Rickels, K., Zaninelli, R., McCafferty, J., Bellew, K., Iyengar, M., & Sheehan, D. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.749 · Cited by 198
Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder
Dunayevich, E., Erickson, J., Levine, L., Landbloom, R., Schoepp, D. D., & Tollefson, G. D. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301531 · Cited by 179
Davidson, J. R. T., Bose, A., Korotzer, A., & Zheng, H. (2004) · Depression and Anxiety · doi:10.1002/da.10146 · Cited by 175
Stein, D. J., Ahokas, A. A., & de Bodinat, C. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318184ff5b · Cited by 174
Maier, W., Gänsicke, M., Freyberger, H. J., Linz, M., Heun, R., & Lecrubier, Y. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101001029.x · Cited by 154
Andreatini, R., Sartori, V. A., Seabra, M. D. L. V., & Leite, J. R. (2002) · Phytotherapy Research · doi:10.1002/ptr.1027 · Cited by 154
Rynn, M. A., Russell, J., Erickson, J., Detke, M. J., Ball, S. G., Dinkel, J., Rickels, K., & Raskin, J. (2007) · Depression and Anxiety · doi:10.1002/da.20271 · Cited by 152
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Pollack, M. H., Simon, N. M., Zalta, A. K., Worthington, J. J., Hoge, E. A., Mick, E. O., Kinrys, G., & Oppenheimer, J. E. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.005 · Cited by 146
Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder
Montgomery, S., Chatamra, K., Pauer, L., Whalen, E., & Baldinetti, F. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037788 · Cited by 146
Boerner, R. J., Sommer, H., Berger, W. L., Kühn, U., Schmidt, U., & Mannel, M. (2003) · Phytomedicine · doi:10.1078/1433-187x-00309 · Cited by 144
Evidence-based pharmacotherapy of Generalized Anxiety Disorder
Baldwin, D. S., & Polkinghorn, C. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004870 · Cited by 143
Self-citationEfficacy and Safety of Hydroxyzine in the Treatment of Generalized Anxiety Disorder
Llorca, P., Spadone, C., Sol, O., Danniau, A., Bougerol, T., Corruble, E., Faruch, M., Macher, J.-P., Sermet, É., & Servant, D. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1112 · Cited by 141
A Meta-analytic Review of the Efficacy of Drug Treatment in Generalized Anxiety Disorder
Mitte, K., Noack, P., Steil, R., & Hautzinger, M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155821.74832.f9 · Cited by 140
Martín, J. L. R., Sainz-Pardo, M., Furukawa, T. A., Martín-Sánchez, E., Seoane, T. M., & Galan, C. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077355 · Cited by 126
Adjunctive Risperidone in Generalized Anxiety Disorder
Brawman‐Mintzer, O., Knapp, R. G., & Nietert, P. J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1016 · Cited by 122
Pollack, M. H., Roy‐Byrne, P., Ameringen, M. V., Snyder, H., Brown, C. E., Ondrasik, J., & Rickels, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1109 · Cited by 122
Silverstone, P. H., & Salinas, E. O. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n07a04 · Cited by 116
Baldwin, D. S., Huusom, A. K. T., & Mæhlum, E. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.012799 · Cited by 114
Self-citationBielski, R. J., Bose, A., & Chang, C.-C. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230590932326 · Cited by 111
Koponen, H., Allgulander, C., Erikson, J., Dunayevich, E., Pritchett, Y., Detke, M. J., Ball, S. G., & Russell, J. M. (2007) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v09n0203 · Cited by 93
Adams, J. B., Pyke, R. E., Costa, J., Cutler, N. R., Schweizer, E. E., Wilcox, C. S., Wisselink, P., Greiner, M., Pierce, M., & Pande, A. C. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199512000-00007 · Cited by 79
Simon, N. M., Connor, K. M., LeBeau, R. T., Hoge, E. A., Worthington, J. J., Zhang, W., Davidson, J. R. T., & Pollack, M. H. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1087-x · Cited by 72
Sertraline Treatment for Generalized Anxiety Disorder
Brawman‐Mintzer, O., Knapp, R. G., Rynn, M. A., Carter, R. E., & Rickels, K. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0603 · Cited by 72
Nicolini, H., Bakish, D., Dueñas, H., Spann, M., Erickson, J., Plascak-Hallberg, C. D., Ball, S. G., Sagman, D., & Russell, J. M. (2008) · Psychological Medicine · doi:10.1017/s0033291708003401 · Cited by 71
Selective Serotonin Reuptake Inhibitor Treatment for Generalized Anxiety Disorder
Ball, S. G., Kuhn, A., Wall, D., Shekhar, A., & Goddard, A. W. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0113 · Cited by 66
Steiner, M. S., Allgulander, C., Ravindran, A. V., Kosar, H., Burt, T., & Austin, C. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.648 · Cited by 64
Aliyev, N. A., & Aliyev, N. A. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.08.001 · Cited by 63
Lenox‐Smith, A., & Reynolds, A. (2003) · Europe PMC (PubMed Central) · Cited by 58
Schmitt, R. L. D. S., Gazalle, F. K., de Lima, M. S., Cunha, A. B. M., Souza, J. S., & Kapczinski, F. P. (2005) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462005000100007 · Cited by 56
Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms.
Sramek, J. J., Tansman, M., Suri, A., Hornig, M., Amsterdam, J. D., Stahl, S. M., Weisler, R. H., & Cutler, N. R. (1996) · PubMed · Cited by 55
Placebo Response in Anxiety Disorders
Piercy, M. A., Sramek, J. J., Kurtz, N. M., & Cutler, N. R. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603000917 · Cited by 51
Generalized anxiety disorder: What are we missing?
Allgulander, C. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.04.002 · Cited by 50
A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.
Bystritsky, A., Kerwin, L. E., Feusner, J. D., & Vapnik, T. (2008) · PubMed · Cited by 48
Nimatoudis, I., Zissis, N. P., Kogeorgos, J., Theodoropoulou, S., Vidalis, A. A., & KAPRINIS, G. S. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200411000-00003 · Cited by 47
Pollack, M. H., Tiller, J., Xie, F., & Trivedi, M. H. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b45f · Cited by 47
Lee, S., Park, J., & Kim, M. (2005) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2005.05181.x · Cited by 37
Ansseau, M., Olié, J., von Frenckell, R., Jourdain, G., Stehlé, B., & Guillet, P. (1991) · Psychopharmacology · doi:10.1007/bf02245646 · Cited by 37
Ballenger, J. C. (2007) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70531-0 · Cited by 27
Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission.
Pollack, M. H. (2001) · PubMed · Cited by 26
Implications of Pain in Generalized Anxiety Disorder: Efficacy of Duloxetine
Hartford, J. T., Endicott, J., Kornstein, S. G., Allgulander, C., Wohlreich, M. M., Russell, J. M., David, P., & Erickson, J. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0304 · Cited by 25
Naukkarinen, H., Raassina, R., Penttinen, J., Ahokas, A., Jokinen, R., Koponen, H., Lepola, U. M., Kanerva, H., Lehtonen, L., Pohjalainen, T., et al. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.03.002 · Cited by 22
Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam
Bourin, M., & Malinge, M. (1995) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(95)00102-2 · Cited by 15
Estimation of symptom-free days in generalized anxiety disorder
Wan, G. J., Zhang, H. F., Tedeschi, M., & Hackett, D. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x96245 · Cited by 12
Ballenger, J. C. (2006) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70236-6 · Cited by 9
Evidence-based pharmacotherapy of generalized anxiety disorder
Baldwin, D. S., Waldman, S., & Allgulander, C. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.008 · Cited by 8
Self-citation
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Optogenetic investigation of neural circuits underlying brain disease in animal models
Tye, K. M., & Deisseroth, K. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3171 · Cited by 745
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Self-citationSlee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., & Freemantle, N. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31793-8 · Cited by 372
Benzodiazepine harm: how can it be reduced?
Lader, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04418.x · Cited by 359
Metadata
- Authors
- Baldwin, D., Woods, R., Lawson, R., & Taylor, D.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2011-03-11
- Volume
- 342
- Issue
- mar11 1
- Pages
- d1199-d1199
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2066770086
- Cited by
- 285
- References
- 64
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.